Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer

Trastuzumab reduces the risk of relapse in women with HER2-positive non-metastatic breast cancer, but little information exists on the timing of trastuzumab initiation. The study investigated the impact of delaying the initiation of adjuvant trastuzumab therapy for >6 months after the breast canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallagher, Christopher M., More, Kenneth, Kamath, Tripthi, Masaquel, Anthony, Guerin, Annie, Ionescu-Ittu, Raluca, Gauthier-Loiselle, Marjolaine, Nitulescu, Roy, Sicignano, Nicholas, Butts, Elizabeth, Wu, Eric Q., Barnett, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869764/
https://www.ncbi.nlm.nih.gov/pubmed/27107569
http://dx.doi.org/10.1007/s10549-016-3790-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869764/
https://www.ncbi.nlm.nih.gov/pubmed/27107569
http://dx.doi.org/10.1007/s10549-016-3790-3

Ejemplares similares